Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study (original) (raw)
2016, Indian Journal of Nephrology
to be from 4.3% to 42% depending upon vintage of MHD in our unit; 42% being at the end of MHD, just before renal transplantation (RT). [2] The major factors affecting the HCV incidence during MHD are nosocomial transmission and transmission through blood and blood component. [3,4] With the development of universal screening of the blood and blood products, nosocomial transmission remains the major route of spread in these patients. We have also shown that chronic liver disease is cause of mortality in RT in the second decade in 25% of the patients at our centers. [5] HCV also increases the risk of serious infection in renal transplant patients. [6] With significant increase in spread of HCV infection
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.